Search clinical trials for: Alexion C5IT

Total 284 results

Portola Pharmaceuticals

Completed

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Bleeding

United States
Portola Pharmaceuticals

Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Bleeding

United States
Portola Pharmaceuticals

Completed

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Healthy
Portola Pharmaceuticals

Terminated

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Bleeding

United States
Portola Pharmaceuticals

Completed

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Healthy Subjects
Portola Pharmaceuticals

Completed

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI (INNOVATE-PCI)

Percutaneous Coronary Intervention

United States, Austria, Canada, Germany, Poland
Portola Pharmaceuticals

Completed

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX)

Venous Thromboembolism (VTE)

Belgium, Israel, Italy, United States, France, Bulgaria, Australia, Germany, Russian Federation, Hungary, Singapore, Austria, Chile, Canada, United Kingdom, Czechia, Poland, Spain, Romania, Latvia, South Africa, Croatia, Serbia, Peru, U... and more
Portola Pharmaceuticals

Completed

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter
Portola Pharmaceuticals

Completed

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa)

Atrial Fibrillation

United States, Canada
Portola Pharmaceuticals

Completed

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Thromboembolism

Canada
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Healthy Volunteers

United States
Alexion

Withdrawn

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

Hypophosphatasia
Portola Pharmaceuticals

Completed

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

Health Volunteers
Portola Pharmaceuticals
Novartis

Terminated

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Portola Pharmaceuticals

Completed

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

Healthy

United States
Alexion

Completed

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

Healthy

United States
Alexion

Completed

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

Healthy

United Kingdom
Alexion

Completed

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Healthy

United States
Alexion

Completed

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Proteinuria

Korea, Republic of
AZ Delta
Alexion

Completed

Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

Thrombosis | PNH

Belgium
Alexion

No longer available

Early Access Program for ALXN1840 in Patients With Wilson Disease

Wilson Disease
Alexion

Completed

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

A Study of a Single Dose of ALXN1210 in Healthy Participants

Healthy

Canada
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Healthy Participants

United States
Alexion

Completed

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Healthy

United States
Alexion

Completed

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

France, United Kingdom, Norway, Russian Federation, Netherlands, United States
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Alexion

Terminated

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (Annexa-S)

Surgery

United States, Germany, Israel, France, Austria, Japan
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Healthy Volunteers

United States
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Withdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Venous Thromboses

United States
Portola Pharmaceuticals

Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

AITL | Peripheral T-Cell Lymphoma (PTCL NOS) | Nodal Lymphomas of T Follicular Helper (TFH) | Follicular T-cell Lymphoma (FTCL) | ALCL | HSTCL | EATL I,II | MEITL, EATL Type II | Nasal Lymphoma
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
Alexion Pharmaceuticals

Completed

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Alexion Pharmaceuticals

Completed

A Study of the Effects of Food and Age on Danicopan

Healthy

United States
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Alexion Pharmaceuticals

Completed

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

Korea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
Alexion Pharmaceuticals

Completed

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

HCV Infection

United States, Germany, Netherlands
Alexion Pharmaceuticals

Completed

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom

3

Subscribe